Earnings Call Insights: Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Jason Kelly, Founder, CEO & Director, emphasized Ginkgo’s mission to "make biology easier to engineer" and outlined three major ...

--Ginkgo Bioworks Holdings, Inc. today announced its results for the third quarter ended September 30, 2025. Excluding this prior year impact, Cell Engineering revenue in the third quarter of 2025 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Ginkgo Bioworks' CEO explains ...

Ginkgo Bioworks' shares have rallied tremendously, and Q2 results showed a headline revenue beat with no upward guidance revision. Biosecurity segment guidance was cut, and overall revenue estimates ...

BOSTON, July 31, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans ...

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It ...

Preprint describes how GPT-5-driven autonomous lab significantly reduced reaction costs in cell-free protein synthesis Ginkgo ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The MarketWatch News Department was not involved in the creation of this content. Ginkgo provides an update on its third quarter financial results BOSTON, Nov. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks ...